Company
Company
No public connections yet.
Arrows show the direction of the relationship. Filter to focus on a business area.
it has expanded its global collaboration and license agreement with argenxView source
Showing 1 to 1 of 1
Read the assertion alongside its sources. Expand a row to inspect the evidence.
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1....
PR Newswire news releases · 2026-10-07 04:05
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1....View source
it has expanded its global collaboration and license agreement with argenx
PR Newswire news releases · 2026-10-07 04:05
it has expanded its global collaboration and license agreement with argenxView source
Showing 1 to 2 of 2
Valuation data is available on Pro and Research.
Included in ProNot available: Company signals · Financials · Filings · Guidance
